TURNOVER UP 39% AT LUNDBECK UK
In the UK, pharmaceutical concern Lundbeck says it is set for a healthy future following its latest annual results. For the year to December 31, 1991, Lundbeck's turnover was L 16.3 million ($28.4 million), an increase of 39% on the previous year.
The company is a subsidiary of Lundbeck A-S of Copenhagen, which in turn is owned by the Lundbeck Foundation. The company is primarily dedicated to the funding of specialist research projects in central nervous system medicine to improve the quality of life for patients suffering from mental illness. The company is also active in the field of oncology.
The year saw the progression of Lundbeck's expansion plans and continued the steady pattern of growth established in 1990, which also enjoyed record results when sales of Lundbeck products exceeded forecasts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze